JPWO2021137148A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021137148A5
JPWO2021137148A5 JP2022534833A JP2022534833A JPWO2021137148A5 JP WO2021137148 A5 JPWO2021137148 A5 JP WO2021137148A5 JP 2022534833 A JP2022534833 A JP 2022534833A JP 2022534833 A JP2022534833 A JP 2022534833A JP WO2021137148 A5 JPWO2021137148 A5 JP WO2021137148A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
group
esketamine
bipolar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507926A (ja
JP2023507926A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/062508 external-priority patent/WO2021137148A1/en
Publication of JP2023507926A publication Critical patent/JP2023507926A/ja
Publication of JP2023507926A5 publication Critical patent/JP2023507926A5/ja
Publication of JPWO2021137148A5 publication Critical patent/JPWO2021137148A5/ja
Pending legal-status Critical Current

Links

JP2022534833A 2019-12-30 2020-12-29 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 Pending JP2023507926A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962954790P 2019-12-30 2019-12-30
US62/954,790 2019-12-30
PCT/IB2020/062508 WO2021137148A1 (en) 2019-12-30 2020-12-29 Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Publications (3)

Publication Number Publication Date
JP2023507926A JP2023507926A (ja) 2023-02-28
JP2023507926A5 JP2023507926A5 (https=) 2024-01-09
JPWO2021137148A5 true JPWO2021137148A5 (https=) 2024-01-09

Family

ID=76545729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534833A Pending JP2023507926A (ja) 2019-12-30 2020-12-29 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画

Country Status (2)

Country Link
US (3) US12478592B2 (https=)
JP (1) JP2023507926A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EA032013B1 (ru) 2013-10-31 2019-03-29 Сайма Лэбс Инк. Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
DK3272338T3 (da) 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
AU2015343083B2 (en) 2014-11-04 2020-07-23 Acadia Pharmaceuticals Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20190240184A1 (en) 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
ES2991544T3 (es) 2016-11-30 2024-12-04 Wolfson Philip E Ketamina para el tratamiento de síntomas relacionados con la menstruación
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) * 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Similar Documents

Publication Publication Date Title
Hoy Dupilumab: a review in chronic rhinosinusitis with nasal polyps
JP4634008B2 (ja) ２ｈ−ベンズイミダゾール−２−オン、１，３−ジヒドロ−１−（２−｛４−［３−（トリフルオロメチル）フェニル］−１−ピペラジニル｝エチル）−及びその生理学的に許容される酸付加塩の新規使用
TWI306120B (en) Method of identifying hungtington's disease patients who will respond to epa treatment and related use of epa
CN101208092A (zh) 用于处理精神障碍的方法和组合物
Zhao et al. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson’s disease
US12364672B2 (en) Esketamine for use in treating major depressive disorder
WO2021137147A1 (en) Dosage regime with esketamine for treating major depressive disorder
AU2019352028A1 (en) Dosage regime of esketamine for treating major depressive disorder
KR20170104597A (ko) 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현
US20150313903A1 (en) Methods of treating cognitive impairment associated with neurodegenerative disorders
JP2021511365A5 (https=)
EP3197445B1 (en) Proline or proline derivatives for the treatment of dementia
JP2023507926A (ja) 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
Shi et al. Neuroprotective role of dexmedetomidine pretreatment in cerebral ischemia injury via ADRA2A-mediated phosphorylation of ERK1/2 in adult rats
JPWO2021137148A5 (https=)
WO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
Connemann et al. Ziprasidone in Parkinson's disease psychosis
de Silva et al. Chronic catatonia treated with electroconvulsive therapy: a case report
JPWO2020003195A5 (https=)
Berigan Modafinil treatment of excessive sedation associated with divalproex sodium
Mughal et al. Trofinetide receives FDA approval as first drug for Rett syndrome
Bschor et al. Is successful lithium augmentation limited to serotonergic antidepressants?
Westphal Cystic Fibrosis: Treatment with CFTR Modulators
WO2021010348A1 (ja) うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１